Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 to treat ovarian cancer and metastatic castration-resistant prostate cancer. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1).
Rucaparib inhibits the contraction of isolated vascular smooth muscle, including that from the tumours of cancer patients. It also reduces the migration of some cancer and normal cells in culture.
Rucaparib powder form is slightly soluble in water.